Get the Stockscreener App
12.66
1.17%
-0.15
After Hours:
12.66
Cogent Biosciences Inc stock is traded at $12.66, with a volume of 1.78M.
It is down -1.17% in the last 24 hours and up +9.61% over the past month.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
See More
Previous Close:
$12.81
Open:
$12.845
24h Volume:
1.78M
Relative Volume:
0.66
Market Cap:
$1.44B
Revenue:
-
Net Income/Loss:
$-284.08M
P/E Ratio:
-7.1124
EPS:
-1.78
Net Cash Flow:
$-234.65M
1W Performance:
-2.99%
1M Performance:
+9.61%
6M Performance:
+66.80%
1Y Performance:
+23.27%
1-Day Range:
$12.28
$13.13
1-Week Range:
$12.28
$13.13
52-Week Range:
$3.72
$13.50
Cogent Biosciences Inc Stock (COGT) Company Profile
Name
Cogent Biosciences Inc
Sector
Industry
Phone
617-945-5576
Address
275 WYMAN STREET, WALTHAM
Compare COGT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
12.66 | 1.78B | 0 | -284.08M | -234.65M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-11-24 | Downgrade | Needham | Buy → Hold |
| Feb-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-08-24 | Initiated | Citigroup | Buy |
| Dec-11-23 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-23 | Initiated | JP Morgan | Overweight |
| Apr-28-23 | Initiated | Robert W. Baird | Outperform |
| Mar-27-23 | Resumed | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Jun-28-22 | Initiated | Guggenheim | Buy |
| Oct-11-21 | Initiated | H.C. Wainwright | Buy |
| Jun-09-21 | Resumed | Jefferies | Buy |
| Dec-23-20 | Initiated | Piper Sandler | Overweight |
| Oct-14-20 | Initiated | Ladenburg Thalmann | Buy |
View All
Cogent Biosciences Inc Stock (COGT) Latest News
Trexquant Investment LP Has $1.10 Million Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
One Cogent Biosciences Insider Raised Stake By 2,085% In Previous Year - Yahoo Finance
Invesco Ltd. Buys 30,102 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Exome Asset Management LLC Invests $3.72 Million in Cogent Biosciences, Inc. $COGT - MarketBeat
What is Cogent Biosciences Inc. s 5 year growth outlook2025 Bull vs Bear & High Yield Stock Recommendations - Lancaster City Council
Gastrointestinal Stromal Tumor Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Deciphera, Blueprint Medicines, Bayer, Cogent Biosciences, GSK - Barchart.com
Cogent Biosciences (NASDAQ:COGT) Sets New 12-Month HighStill a Buy? - MarketBeat
Published on: 2025-09-09 06:41:27 - beatles.ru
Cogent Biosciences (NASDAQ:COGT) Trading Up 11.1%Still a Buy? - MarketBeat
Redmile Group LLC Cuts Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Certain Common Stock of Cogent Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 7-SEP-2025. - MarketScreener
Certain Performance-based Restricted Stock Units of Cogent Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 7-SEP-2025. - MarketScreener
Certain Restricted Stock Units of Cogent Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 7-SEP-2025. - MarketScreener
Can volume confirm reversal in Cogent Biosciences Inc.Earnings Overview Summary & Weekly Breakout Stock Alerts - Newser
Is Cogent Biosciences Inc. still worth holding after the dipMarket Growth Report & Safe Capital Growth Tips - Newser
Can Cogent Biosciences Inc. ride the EV wave2025 Market Sentiment & Stepwise Trade Signal Guides - خودرو بانک
Will Cogent Biosciences Inc. benefit from government policyMarket Sentiment Report & Risk Adjusted Buy and Sell Alerts - خودرو بانک
Is Cogent Biosciences Inc. attractive for institutional investorsJuly 2025 Big Picture & Reliable Volume Spike Alerts - خودرو بانک
Volatility clustering patterns for Cogent Biosciences Inc.Weekly Trade Recap & High Return Trade Opportunity Guides - Newser
Is Cogent Biosciences Inc. forming a bullish divergence2025 Trading Volume Trends & Consistent Profit Alerts - خودرو بانک
Real time alert setup for Cogent Biosciences Inc. performanceMarket Activity Recap & Precise Buy Zone Tips - Newser
Will Cogent Biosciences Inc. rebound enough to break evenTrade Ideas & Daily Stock Trend Reports - Newser
Paradigm Biocapital Advisors LP Buys 4,046,243 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Reversal indicators forming on Cogent Biosciences Inc. stockQuarterly Profit Summary & Fast Momentum Entry Tips - Newser
What’s the recovery path for long term holders of Cogent Biosciences Inc.July 2025 Trade Ideas & Free Technical Confirmation Trade Alerts - Newser
Will breakout in Cogent Biosciences Inc. lead to full recoveryRate Hike & Technical Confirmation Trade Alerts - Newser
Cogent Biosciences Inc. stock daily chart insightsEarnings Miss & AI Driven Stock Price Forecasts - Newser
Technical analysis overview for Cogent Biosciences Inc. stockSell Signal & Reliable Price Action Trade Plans - Newser
Using economic indicators to assess Cogent Biosciences Inc. potentialWeekly Earnings Recap & Weekly Top Gainers Trade List - Newser
Live market analysis of Cogent Biosciences Inc.2025 Performance Recap & Consistent Income Trade Ideas - Newser
How sentiment analysis helps forecast Cogent Biosciences Inc.Buy Signal & Technical Pattern Based Signals - Newser
How to use Fibonacci retracement on Cogent Biosciences Inc.Quarterly Risk Review & Weekly Momentum Stock Picks - Newser
Is Cogent Biosciences Inc. in a bullish channelLong Setup & Weekly Momentum Stock Picks - خودرو بانک
Combining price and volume data for Cogent Biosciences Inc.2025 Valuation Update & Long-Term Growth Stock Strategies - Newser
Using AI based signals to follow Cogent Biosciences Inc.Quarterly Portfolio Report & Real-Time Buy Zone Alerts - Newser
Raymond James Initiates Coverage on Cogent Biosciences (COGT) wi - GuruFocus
Cogent Biosciences’ Strategic Position in the Evolving Biopharma Landscape - AInvest
Transcript : Cogent Biosciences, Inc. Presents at Citi's Biopharma Back to School Conference, Sep-03-2025 09 - MarketScreener
Is Cogent Biosciences Inc. stock risky to hold nowQuarterly Risk Review & Verified High Yield Trade Plans - خودرو بانک
Cogent Biosciences stock hits 52-week high at 13.01 USD - Investing.com
Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday - Benzinga
Raymond James Initiates Cogent Biosciences at Strong Buy - MarketScreener
What makes Cogent Biosciences Inc. stock price move sharplyJuly 2025 Trends & Risk Controlled Daily Trade Plans - Newser
Is it too late to sell Cogent Biosciences Inc.Long Setup & Accurate Buy Signal Alerts - Newser
Investment Report: Is Cogent Biosciences Inc. forming a bullish divergenceMarket Performance Summary & Stepwise Swing Trade Plans - خودرو بانک
Institutional scanner results for Cogent Biosciences Inc.Breakout Watch & Low Drawdown Momentum Ideas - Newser
How cyclical is Cogent Biosciences Inc.’s revenue streamQuarterly Earnings Report & Free Community Consensus Stock Picks - خودرو بانک
Developing predictive dashboards with Cogent Biosciences Inc. dataInflation Watch & Daily Oversold Bounce Ideas - Newser
Walleye Capital LLC Trims Stake in Cogent Biosciences, Inc. $COGT - MarketBeat
Is Cogent Biosciences Inc. stock a value trapJuly 2025 Institutional & Weekly Top Gainers Trade List - beatles.ru
Aug Big Picture: Can Cogent Biosciences Inc. ride the EV waveIPO Watch & High Return Trade Guides - خودرو بانک
Cogent Biosciences Inc Stock (COGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):